Completed Enrollment

A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

The reason for this study is to see if the study drug ixekizumab is safe and effective in children with juvenile idiopathic arthritis (JIA) categories of enthesitis-related arthritis (ERA) (including juvenile onset ankylosing spondylitis [JoAS]) and juvenile psoriatic arthritis (JPsA).

Trial Summary

Age Range
2 - 17 years
Conditions the trial is for
Arthritis
What the trial is testing?
Ixekizumab, Adalimumab
Could I receive a Placebo?
No
Enrollment Goal
100
Trial Dates
Apr 13, 2021 - Apr 2028
How long will I be in the trial?
The study will last about 120 weeks and may include up to 32 visits.
Trial Phase
III

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participants must have active juvenile idiopathic arthritis (categories of enthesitis related arthritis or juvenile psoriatic arthritis)

  • Participants must have weight of at least 10 kilograms (Kg), age starting at 2 years for participants with juvenile psoriatic arthritis and starting at 6 years for participants with enthesitis related arthritis

  • Participants must have all immunizations up-to-date in agreement with current immunization guidelines, in the opinion of the investigator

Participants Must Not:

  • Participants must not have active or history of inflammatory bowel disease

  • Participants must not have active uveitis

  • Participants must not have active or latent tuberculosis

  • Participants must not have an active infection

  • Participants must not have concurrent use of biologic agents for the treatment of the juvenile idiopathic arthritis

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.

Clinical Trial Resources